EMCURE

Emcure Pharmaceuticals Share Price

₹1,212.75 -72.5 (-5.64%)

08 Feb, 2025 02:01

SIP TrendupStart SIP in EMCURE

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -15.35%
  • Over 3 Month -16.08%
  • Over 6 Month -6.34%
  • Over 1 Year + 20.31%
SIP Lightning

Smart Investing Starts Here Start SIP with Emcure Pharmaceuticals for Steady Growth!

Invest Now

Emcure Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Emcure Pharmaceuticals Financials

Emcure Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,212.75
-72.5 (-5.64%)
pointer
  • stock-down_img
  • Bearish Moving Average 13
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,282.60
  • 50 Day
  • ₹1,332.67
  • 100 Day
  • ₹1,356.87
  • 200 Day
  • -

Resistance and Support

1239.5 Pivot Speed
  • R3 1,397.50
  • R2 1,353.75
  • R1 1,283.25
  • S1 1,169.00
  • S2 1,125.25
  • S3 1,054.75

What's your outlook on Emcure Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Emcure Pharmaceuticals manufactures and markets a wide range of pharmaceutical products, including generics, biosimilars, and injectables. With a global presence in 70+ countries, it focuses on affordable healthcare solutions across therapeutic areas like cardiology, oncology, and women’s health.

Emcure Pharmaceuticals Ltd has an operating revenue of Rs. 7,551.11 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 11% is healthy, ROE of 16% is good. The company has a reasonable debt to equity of 26%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 18% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 46 which is a POOR score indicating inconsistency in earnings, a RS Rating of 41 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 33 indicates it belongs to a strong industry group of Medical-Supplies and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Emcure Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-06 Quarterly Results
2024-11-07 Quarterly Results
2024-08-13 Quarterly Results

Emcure Pharmaceuticals F&O

Emcure Pharmaceuticals Shareholding Pattern

77.94%
3.1%
0.36%
3.05%
5.14%
10.41%

About Emcure Pharmaceuticals

  • NSE Symbol
  • EMCURE
  • BSE Symbol
  • 544210
  • Managing Director & CEO
  • Mr. Satish Ramanlal Mehta
  • ISIN
  • INE168P01015

Similar Stocks to Emcure Pharmaceuticals

Emcure Pharmaceuticals FAQs

Emcure Pharmaceuticals share price is ₹1,212 As on 08 February, 2025 | 01:47

The Market Cap of Emcure Pharmaceuticals is ₹22973.3 Cr As on 08 February, 2025 | 01:47

The P/E ratio of Emcure Pharmaceuticals is 37.8 As on 08 February, 2025 | 01:47

The PB ratio of Emcure Pharmaceuticals is 5.6 As on 08 February, 2025 | 01:47

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23